AstraZeneca reports baxdrostat met primary endpoint in Bax24 trial

Results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure compared with placebo at 12 weeks. Efficacy was observed throughout the 24-hour period, including early morning, when patients with hypertension are at a higher risk of cardiovascular events. Patients with treatment-resistant hypertension received baxdrostat 2mg or placebo on top of standard of care. Baxdrostat was generally well tolerated, with a safety profile consistent with the BaxHTN trial. The data will be shared with regulatory authorities around the world and presented in a late-breaking session at the American Heart Association Scientific Sessions in November.